Stock Research: Ipsen

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Ipsen

ENXTPA:IPN FR0010259150
90
  • Value
    90
  • Growth
    39
  • Safety
    Safety
    77
  • Combined
    88
  • Sentiment
    69
  • 360° View
    360° View
    90
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Ipsen SA is a biopharmaceutical group specializing in specialty care. The company operates in the specialty care and consumer healthcare industries, with a focus on oncology, neurosciences, and rare diseases. It operates globally, with research and development centers in France, the United Kingdom, and the United States. In the last fiscal year, the company had a market cap of $10,169 million, profits of $3,060 million, and revenue of $3,701 million, with 5358 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 90 (better than 90% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Ipsen are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Ipsen. The consolidated Value Rank has an attractive rank of 77, which means that the share price of Ipsen is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 77% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 90. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 69. But the consolidated Growth Rank has a low rank of 39, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 61 of its competitors have better growth. ...read more

more
Index
CAC All
SBF 120
Employee Focus EU
Moonshot Tech
Renewables Users
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out
Learn More

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
77 86 67 82
Growth
39 47 21 75
Safety
Safety
90 69 54 62
Sentiment
69 27 48 80
360° View
360° View
90 74 45 98
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
19 11 24 19
Opinions Change
73 18 43 92
Pro Holdings
n/a 69 61 82
Market Pulse
77 49 71 41
Sentiment
69 27 48 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
77 86 67 82
Growth
39 47 21 75
Safety Safety
90 69 54 62
Combined
88 81 38 94
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
82 89 81 92
Price vs. Earnings (P/E)
47 53 52 79
Price vs. Book (P/B)
60 67 57 69
Dividend Yield
49 52 49 53
Value
77 86 67 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
25 47 46 20
Profit Growth
39 23 25 63
Capital Growth
56 80 7 88
Stock Returns
59 55 62 70
Growth
39 47 21 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
84 78 68 41
Refinancing
61 25 15 48
Liquidity
81 76 75 65
Safety Safety
90 69 54 62

Similar Stocks

Discover high‑ranked alternatives to Ipsen and broaden your portfolio horizons.

Rubis

ENXTPA:RUI
Country: France
Industry: Gas Utilities
Size: Medium
Full Stock Analysis

Societe Generale

ENXTPA:GLE
Country: France
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

Savencia

ENXTPA:SAVE
Country: France
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.